The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDestiny Pharma. Share News (DEST)

Share Price Information for Destiny Pharma. (DEST)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.25
Bid: 18.00
Ask: 18.50
Change: 0.00 (0.00%)
Spread: 0.50 (2.778%)
Open: 18.25
High: 18.25
Low: 18.25
Prev. Close: 18.25
DEST Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK EXECUTIVE CHANGE SUMMARY: Martin Gilbert Joins River & Mercantile

Wed, 06th Jan 2021 14:27

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Wednesday and not separately reported by Alliance News:

----------

River & Mercantile Group PLC - Hires Martin Gilbert to be deputy chair, starting Wednesday. Gilbert was the co-founder and then chief executive of Aberdeen Asset Management, now Standard Life Aberdeen PLC. He currently is chair of lender Revolut Ltd and senior independent director of miner Glencore PLC. "In the current environment there are market opportunities for RMG, both organic and through acquisitions, that can drive shareholder value," Gilbert says. River & Mercantile had GBP45.4 billion in assets under management as of September 30.

----------

Fulcrum Utility Services Ltd - Sheffield-based multi-utility infrastructure and services provider - Daren Harris steps down as chief executive officer and from board, effective immediately. Chief Operating Officer Terry Dugdale, in post since March 2019, becomes CEO. "The business is well placed with strong market drivers and a robust balance sheet and its strategy is strongly positioned to capitalise on the UK's journey to net zero," Harris says. "Unfortunately, due to personal reasons, I need to step down from the business." He adds: "Since joining the business, Terry has driven our operating efficiency and has made significant progress in preparing the business foundations for the future."

----------

Silence Therapeutics PLC - London-based novel short interfering ribonucleic acid therapeutics developer - Hires Craig Tooman as chief financial officer, effective immediately. Tooman was most recently CFO & COO of Princeton, New Jersey-based Vyome Therapeutic Inc. Silence also says Michael Davidson has joined the Silence board as non-executive director. Davidson currently is CEO of New Amsterdam Pharma BV and a professor of medicine at the Lipid Clinic at the University of Chicago. He founded Omthera Pharmaceuticals in 2008, which was acquired by AstraZeneca PLC in 2013, and was founding CEO of Corvidia Therapeutics, which was acquired by Novo Nordisk AS in 2020.

----------

Personal Group Holdings PLC - Milton Keynes, Buckinghamshire-based provider of employee services - Makes Interim CFO Sarah Mace its permanent CFO, effective immediately. Mace was promoted to the board as interim CFO back in October, having joined Personal Group in 2014.

----------

Kape Technologies PLC - Isle of Man-based digital security and privacy software company - Hires Pierre-Etienne Lallia as non-executive director, effective immediately. Lallia spent 10 years at Nomura International PLC in London, where he was managing director of the Acquisition & Leveraged Finance team. Prior to that, he was with Goldman Sachs International, part of Goldman Sachs Group Inc.

----------

Time Finance PLC - Bath, England-based finance provider to UK small and medium businesses - Non-Executive Chair John Newman and CEO Ian Smith both to retire once successors are found. Says process for replacing the pair is underway. Says Smith's decision follows rebranding of company from 1pm PLC early last month and his previous intention to retire in any event at the end of 2021.

----------

Destiny Pharma PLC - Brighton-based clinical stage biotechnology firm focused on preventing infections - Hires Stephanie Bewick as chief business officer. Bewick was vice president for Business Development at Nasdaq-listed Summit Therapeutics Inc.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
1 Nov 2018 13:09

Destiny Pharma Biofilm Project With Southampton Uni Secures Funding

LONDON (Alliance News) - Destiny Pharma PLC said Thursday it had been jointly granted funding with the University of Southampton to examine the use of its technology to eradicate clinical caused a

Read more
25 Oct 2018 11:23

Destiny Pharma Hires Creabilis's Shaun Claydon As New Finance Head

LONDON (Alliance News) - Destiny Pharma PLC said on Thursday it has appointed Shaun Claydon as its new finance chief after the departure of Chief Financial Officer Simon Sacerdoti.Claydon,

Read more
19 Oct 2018 14:54

Destiny Pharma helps with new bioindustry association videos

(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma noted the launch of a series of videos and explainer documents from the UK BioIndustry Association (BIA) celebrating UK bioscience and revealing the research and development taking place in biotech companies around the UK on Friday.

Read more
26 Sep 2018 12:39

Destiny Pharma Loss More Than Doubles On Administrative Expenses

LONDON (Alliance News) - Destiny Pharma PLC on Wednesday reported a substantial widening of its loss in the first half of the year due to administrative expenses.The clinical stage company

Read more
6 Sep 2018 13:24

Destiny Pharma Chairman Nigel Rudd To Step Down In December

LONDON (Alliance News) - Destiny Pharma PLC said Thursday that Chairman Nigel Rudd stepped down from the company in December after eight years.Non-Executive Director Nick Rodgers will Rudd

Read more
6 Sep 2018 10:32

Chairman of Destiny calling time after 15 years with pharma firm

(Sharecast News) - Clinical stage biotechnology firm Destiny Pharma revealed on Thursday that long-time chairman Nigel Rudd was stepping down from the board on 31 December after eight years.

Read more
26 Jul 2018 13:49

Destiny Pharma Receives Positive Results From Skin Irritation Study

LONDON (Alliance News) - Destiny Pharma PLC said Thursday that it received positive data from the Phase I of its XF-73 skin irritation study.The clinical stage biotechnology company said is

Read more
21 Jun 2018 10:25

Destiny Pharma Appoints SEHTA Chairman Nick Rodgers As Non-Executive

LONDON (Alliance News) - Anti-microbial resistance-focused biotechnology developer Destiny Pharma PLC said Thursday it has appointed Nick Rodgers as an independent non-executive director with is a

Read more
30 May 2018 13:00

Destiny Pharma Creates Independent Scientific Advisory Board

LONDON (Alliance News) - Destiny Pharma PLC said Wednesday it has formed a scientific advisory board to provide "expert, independent analysis" of the company's research and clinical

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.